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Severe postnatally acquired cytomegalovirus infection presenting
with colitis, pneumonitis and sepsis-like syndrome in an
extremely low birthweight infant
Abstract
Few cases of severe postnatally acquired cytomegalovirus (CMV) infection are reported in premature
infants. We report on an extremely low birthweight (ELBW) preterm infant who presented with a
sepsis-like syndrome and multiple organ involvement, notably pneumonitis and colitis. The course of
infection was assessed by repeated analysis of urine, tracheal aspirates and blood. The patient was given
intravenous ganciclovir. The clinical course was rapidly favorable. Development of neutropenia led to
the discontinuation of the antiviral treatment after 28 days. Follow-up showed moderate white matter
anomalies on cerebral MRI, a transient hypoacusis and a mild developmental delay at 18 months of
corrected age. To the best of our knowledge, this is the first description of a severe combination of
pneumonitis and colitis in postnatal CMV infection. Many issues remain controversial and are
discussed. We propose that antiviral treatment should be considered in severe postnatal CMV infection
in ELBW patients.
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 Abstract 
 Few cases of severe postnatally acquired cytomegalovirus 
(CMV) infection are reported in premature infants. We report 
on an extremely low birthweight (ELBW) preterm infant who 
presented with a sepsis-like syndrome and multiple organ 
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 Established Facts 
 • Postnatal cytomegalovirus infection can lead to symptomatic disease in a preterm infant with a broad 
spectrum of clinical manifestations .
 • Clinical course of the infection is difficult to assess. 
 • Knowledge about the efficiency of antiviral treatment is very limited. 
 • Many long-term issues remain uncertain. 
 Novel Insights 
 • Association of pneumonitis and colitis with severe clinical deterioration is a rare presentation of the 
disease in extremely low birthweight infants.
 • Repeated analysis in urine, blood and tracheal aspirates were performed to assess the evolution of the 
infection. 
 • Intravenous ganciclovir should be considered for severe postnatal cytomegalovirus infection in ex-
tremely low birthweight patients. 
 • Careful long-term neurosensorial and developmental follow-up is needed. 
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involvement, notably pneumonitis and colitis. The course of 
infection was assessed by repeated analysis of urine, trache-
al aspirates and blood. The patient was given intravenous 
ganciclovir. The clinical course was rapidly favorable. Devel-
opment of neutropenia led to the discontinuation of the an-
tiviral treatment after 28 days. Follow-up showed moderate 
white matter anomalies on cerebral MRI, a transient hy-
poacusis and a mild developmental delay at 18 months of 
corrected age. To the best of our knowledge, this is the first 
description of a severe combination of pneumonitis and 
colitis in postnatal CMV infection. Many issues remain con-
troversial and are discussed. We propose that antiviral treat-
ment should be considered in severe postnatal CMV infec-
tion in ELBW patients.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Although cytomegalovirus (CMV) infection is well 
recognized as a leading cause of congenital pathology as-
sociated with important morbidity and mortality, less is 
known about CMV infection if acquired in the early 
postnatal period  [1] . Postnatal CMV infection is most of-
ten transmitted through breastfeeding  [2] . Other sources 
of perinatal and postnatal infection are cervical and vag-
inal secretions, blood transfusions and horizontal trans-
mission by close contact. In contrast to the usually 
 asymptomatic course in term neonates, postnatal infec-
tion in preterm infants can lead to a broad spectrum of 
potentially life-threatening problems  [2, 3] . Only a few 
cases of such infections have been reported  [4–7] . Major 
aspects like the natural evolution of the disease, thera-
peutic options or long-term outcome remain poorly rec-
ognized or controversial. We report here a case of post-
natal CMV infection in an extremely low birthweight 
(ELBW) infant. He presented sudden clinical deteriora-
tion with sepsis-like symptoms, pneumonitis, colitis, 
hepatomegaly and thrombocytopenia, and showed rapid 
recovery under antiviral treatment. His neurodevelop-
mental follow-up until 18 months of corrected age is de-
scribed.
 Case Report 
 A 26-year-old primigravida vaginally delivered a male pre-
term infant at 24 6/7 weeks of gestation after preterm labor due to 
suspected chorioamnionitis. At the time of birth, pulmonary 
maturation with betamethasone had just been initiated. Birth-
weight was 780 g (P10–50th), body length 33.5 cm (P50–90th) and 
head circumference 23.5 cm (P50–90th). Apgar score was 1, 6 and 
8 at 1, 5 and 10 min, respectively. The initial course was marked 
by a severe respiratory distress syndrome requiring intubation, 
repeated doses of exogenous surfactant and prolonged mechani-
cal ventilation, relayed by nasal continuous positive airway pres-
sure (nCPAP) starting on day of life (DOL) 50. Apneas were treat-
ed with caffeine citrate. Three courses of antibiotics were applied 
within the first month due to bouts of clinical deterioration for 
which no infectious agent could be isolated. Several erythrocyte 
transfusions were required between DOL 2 and 49. Enteral nutri-
tion was started on DOL 2 giving a few milliliters of fresh colos-
trum, progressing with an increment of 10 ml/kg/day to reach 140 
ml/kg/day of exclusive mother’s breast milk on day 14. All milk 
was frozen at –20 ° C at our nutrition center 2–30 days before ad-
ministration. Pasteurization was not performed. Growth was ini-
tially retarded and then followed the 25th percentile.
 On DOL 58 (corresponding to 33 1/7 weeks of gestational age) 
the infant presented bloody stools while maintaining a good gen-
eral condition and a normal abdominal status.  Table 1  summa-
rizes the main relevant clinical events, laboratory findings and 
radiological studies. Blood count showed thrombocytopenia, 
lymphocytosis and neutropenia. Three days later, he showed ab-
dominal distension, hepatosplenomegaly and bloody diarrhea, 
along with rapidly progressing respiratory distress and increased 
oxygen requirements. Simultaneously, his general condition de-
teriorated with apathy, hypotonia, grayish discoloration, fever, 
and many severe episodes of apnea and bradycardia requiring en-
dotracheal intubation. The gastric tube was placed under inter-
mittent aspiration. Laboratory findings revealed increasing in-
flammatory parameters (CRP 146 mg/l, leukocytosis with shift-
ing to immature cells) and persistence of thrombocytopenia. Se - 
rum levels of transaminases and liver function remained within 
the normal range. Abdominal X-rays showed diffuse distension 
of the gastrointestinal tract with no signs of pneumatosis or per-
foration. Chest X-ray revealed diffuse bilateral alveolar infiltra-
tions with predominance on the right side. Empirical antibiotic 
therapy was initiated with a combination of ceftazidime, amika-
cin and metronidazole and continued for 10 days. All cultures for 
bacterial pathogens (blood, urine, tracheal aspirates and stool) 
obtained before initiation of antibiotic treatment were found to be 
sterile. A lumbar puncture was not performed due to the child’s 
critical and unstable clinical condition. A CMV infection was 
suspected considering the infant’s unusual age and atypical clin-
ical picture for necrotizing enterocolitis, the negative culture re-
sults together with the concomitant and persistent thrombocyto-
penia. CMV infection was confirmed by testing urine for CMV 
DNA with polymerase chain reaction (PCR), revealing a high vi-
ral load (581,100 copies/ml). DNA was extracted on a MagNA 
Pure LC  machine using the DNA Isolation Kit I (Roche Diag-
nostics, Mannheim, Germany) according to the manufacturer’s  
instructions  and  amplified  for  CMV  pp65  (UL83) DNA using 
the forward primer CMVPP65_F (5  ACGGCTTTACGGTG-
TTGTGTC3  ) and the reverse primer CMVPP65_R (GCAGCC-
CAAAATGCTCGTGTG). The reactions were performed in a fi-
nal volume of 20   l, including 0.2   M of each primer, 0.1   M 
Ctr_P probe, 10   l 2 ! TaqMan Universal Master Mix (Applied 
Biosystems, Foster City, Calif., USA) and 5   l DNA sample. Cy-
cling conditions were 2 min at 50 ° C, 10 min at 95 ° C, followed by 
45 cycles of 15 s at 95 ° C and 1 min at 60 ° C. Amplification and 
PCR product detection were performed with the ABI Prism 7900 
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Sequence Detection system (Applied Biosystems). This PCR sys-
tem has been validated clinically  [8] . The infant’s blood obtained 
on DOL 58 was also found to be positive for CMV DNA by PCR. 
This analysis was performed retrospectively on a dried blood 
sample of a neonatal screening card which was performed on the 
same day. DNA was extracted using the QIAmp DNA mini kit 
(Qiagen, Hilden, Germany). CMV DNA analysis was performed 
using the TaqMan real-time PCR technique as described earlier 
 [9] . Several complementary investigations were performed in an 
attempt to rule out a congenital infection and to date the acquisi-
tion of the virus by the child. The maternal serological status for 
CMV had checked positive for IgG but negative for IgM at 12 
weeks of gestation. PCR testing for CMV on a specimen of blood 
obtained on DOL 1 before the first blood transfusion (kept as a 
dried sample on another neonatal screening card) was negative 
 [10] . Reexamination of placental histology showed neither giant 
cells nor cell inclusions. Endotracheal secretions, that had been 
obtained at different time points throughout the whole hospital-
ization period, were retrospectively tested by PCR for CMV DNA. 
Viral DNA was undetectable on DOL 40 and detected on DOL 50, 
i.e. 10 days before the onset of respiratory symptoms. Weighing 
up psychological and ethical considerations (protect the mother 
from guilt feelings, preserve breastfeeding, and knowing that the 
clinical course, treatment and prognosis of the infant would not 
be influenced by the result), we intentionally did not perform 
CMV analysis in mother’s milk. However, we excluded the other 
important route of transmission by re-testing transfused blood 
samples. Due to the persistent critical condition, antiviral therapy 
with intravenous ganciclovir was introduced on DOL 62 (12 mg/
kg body weight in 2 daily doses) and was associated with a rapid 
improvement in clinical, biological and radiological parameters. 
The patient was completely free of symptoms 1 week after starting 
antiviral treatment and could be extubated on the 8th day of ther-
apy. Enteral feeding was resumed shortly thereafter without com-
Table 1. Synopsis of clinical, radiological and laboratory data of the reported case
DOL Clinical signs Radiology Hematology Chemistry Virology (PCR) Treatment
1 Blood negative
40 Tracheal secretions 
negative
50 Tracheal secretions 
positive
365 copies/ml
52 Leukopenia (5.6!109/l)
Thrombocytopenia (112!109/l)
CRP <2 mg/l
57 Neutropenia (0.97!109/l)
Lymphocytosis
Thrombocytopenia (34!109/l)
Urine positive
581,100 copies/ml
58 Bloody stool
Good general condition
Normal abdominal examination
Unchanged Blood positive
61 Hypotonia, fever, gray color, 
apnea, increased oxygen 
requirements, painful abdominal 
distension, hepatosplenomegaly, 
bloody diarrhea
Chest X-ray:
diffuse bilateral 
pulmonary 
infiltrates
Unchanged CRP 101 mg/l Intubation
Gastric aspiration
Antibiotics (10 days)
62 Unchanged clinical picture Cerebral US:
normal
Leukocytosis (23.6!109/l), left shift
Anemia (hemoglobin 122 g/l)
Thrombocytopenia (57!109/l)
CRP 146 mg/l
Normal hepatic 
values
Red cell transfusion
Ganciclovir (28 days)
66 General condition improved, 
normalization of stool, liver and 
abdominal status
Thrombocytopenia (78!109/l) Tracheal 
secretions 
negative
69 Asymptomatic Cerbral MRI:
moderate 
diffuse anomaly 
of the white 
matter
Thrombocytopenia (97!109/l) CRP 6 mg/l Urine negative Nasal continuous
positive airway 
pressure
Enteral refeeding
79 Neutropenia (0.57!109/l) Urine positive
3,700 copies/ml
DOL = Day of life; CRP = C-reactive protein.
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plication. Ganciclovir was discontinued after 4 weeks of therapy 
because of persistent neutropenia (min 0.4 ! 109/l). Urine test for 
CMV DNA became negative after 1 week of ganciclovir treatment 
but asymptomatic viral shedding reappeared 2 weeks after cessa-
tion of therapy. On DOL 66, tracheal aspirates were free of CMV 
DNA.
 The infant remained on respiratory support with nCPAP dur-
ing another 8 weeks, i.e. until 42 weeks of gestational age. Despite 
the diagnosis of severe bronchopulmonary dysplasia, he was dis-
charged home at 44 weeks of gestational age, weighing 4,180 g 
(P10–50th), free of supplemental oxygen and medical treatment.
 Cerebral ultrasound examination performed on a weekly basis 
remained normal. A first cerebral MRI was obtained on DOL 69 
(i.e. at 34 weeks of gestational age) and repeated at term. Both ex-
aminations showed nonspecific lesions, with moderately high in-
tensity of signal in the periventricular white matter and micro-
hemorrhages in the posterior fossa.
 The ophthalmologic examination revealed a persistent vitre-
ous membrane which disappeared at term. A grade I retinopathy 
was described on DOL 108 but had spontaneously disappeared on 
checkup on DOL 139. Acoustic evoked potentials were moder-
ately abnormal on DOL 132 (i.e. at 43 weeks of gestational age), 
with bilateral hearing loss (50 dB on the left and 30 dB on the right 
side). Follow-up examination at the corrected age of 4 months was 
normal on the right but unchanged on the left side. At 12 months 
it was normal on both sides. Neurological and developmental as-
sessments performed at term, 6 and 12 months of corrected age 
showed mild abnormalities in muscle tone for which he benefited 
from early motor physiotherapy since discharged home. At 18 
months, the child was mildly floppy and the developmental eval-
uation with the ‘Griffiths Scales of Infant Development’ (stan-
dardized at a developmental quotient of 100, with 1 SD = 15) re-
vealed a homogeneous and global delay with a quotient of 74  [11] . 
The patient was then offered an early intervention program.
 Discussion 
 On DOL 61 this very premature ELBW infant devel-
oped a severe sepsis-like syndrome with multiple organ 
involvement including colitis, pneumonitis, thrombocy-
topenia, mild anemia, neutropenia and hepatospleno-
megaly without hepatitis. CMV infection was proven by 
several PCR analyses in blood, urine and endotracheal 
secretions and antiviral therapy was started. Facing such 
a situation, the clinician is confronted with several ques-
tions.
 Timing of Infection? 
 The isolation of CMV in a sample of urine obtained 
later than 2–3 weeks after birth cannot distinguish a con-
genitally from a postnatally acquired infection. However, 
a prenatal infection can be retrospectively diagnosed by a 
positive PCR analysis performed on a sample of dried 
blood from the early postnatal screening card (Guthrie 
test)  [10] . In our case, negative CMV PCR on dried blood 
spot test from DOL 1 and normal placental histology rein-
force the hypothesis of a postnatally acquired infection.
 Source of Infection? 
 Transmission of CMV by the breast milk of seroposi-
tive mothers is well described  [12] . CMV excretion in 
breast milk is at its peak from 3 to 5 weeks postnatally, 
with up to 97% of tested samples yielding CMV DNA 
 [13] . Studies of CMV transmission through breast milk 
reveal a wide range of transmission rates  [14, 15] . This 
likely reflects variations in CMV load of breast milk over 
time and of different standards of milk conservation. Co-
lostrum seems to be at low risk of containing CMV  [16] . 
Freezing milk to –20 ° C reduces but does not abolish the 
risk of infection, as shown by this patient who was exclu-
sively fed with frozen mother’s milk except for a few mil-
liliters of colostrum  [5, 17, 18] .
 Other potential sources of CMV infection include the 
following: (1) Exposure to infected genital secretions in the 
birth canal resulting in a disease starting within the first 6 
postnatal weeks. (2) Infection through transfusion of con-
taminated blood products. This way of transmission can 
be effectively reduced by transfusing blood from CMV-
negative donors and/or by transfusing blood after leuko-
filtration. Both approaches are practiced in our center for 
all neonates needing blood transfusions. (3) Nosocomial 
transmission from congenitally infected hospitalized neo-
nates, or infected caregivers or family members  [1] .
 Clinical Presentation? 
 Shedding of CMV in breast milk almost invariably re-
sults from reactivation of preexistent CMV infection in 
seropositive mothers. The neonates of these mothers are 
usually protected by transplacental transfer of maternal 
antibodies. Ingestion of breast milk containing CMV is 
therefore considered harmless in term neonates. Howev-
er, this protective mechanism does not apply to preterm 
infants in whom the risk of developing an early and symp-
tomatic postnatal CMV infection is directly proportional 
to the degree of immaturity  [19] . Indeed, depending on 
the child’s maturity, the rate of symptomatic infection 
shows a wide variation going up to 75%  [20, 21] . Individ-
ual factors of susceptibility are suspected but so far un-
known. The onset of relevant signs of postnatal CMV in-
fection is reported from DOL 22 to 209  [19] . Manifesta-
tions can vary from hematological signs like neutropenia 
or lymphocytosis, anemia and thrombocytopenia to or-
gan involvement like hepatosplenomegaly with or with-
out hepatitis and cholestasis, pneumonitis, or colitis. In 
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most severe cases, the clinical picture is a severe sepsis-
like disease. A case of hemophagocytic lymphohistiocy-
tosis-like syndrome has recently been described  [22] . Fur-
thermore, our patient presented a multiorgan involve-
ment. Pneumonitis was suggested by apnea, respiratory 
distress, increasing oxygen and ventilatory needs. Chest 
X-ray initially showed a bilateral reticulo-granular pat-
tern compatible with CMV pneumonitis. We were able to 
document the presence of CMV in periodic tracheal aspi-
rate samples, interestingly, from 10 days before to 5 days 
after the onset of symptoms, while all bacterial cultures 
remained sterile, suggesting but not proving an etiologi-
cal role for this virus. Additionally, the patient manifested 
concomitant signs of a hemorrhagic colitis with impor-
tant abdominal distension and bloody diarrhea, which 
might be a hint to the enteral route of infection. An etio-
logic role of CMV infection in enterocolitis has recently 
been suggested  [23] . We hypothesized that an enterocoli-
tis due to CMV infection could have favored bacterial 
translocation and infection via an altered intestinal mu-
cosa. This could explain the unusually high CRP value  [3] . 
However, as all blood and stool cultures remained nega-
tive we cannot prove this hypothesis.
 Antiviral Therapy? 
 No controlled study has yet evaluated the impact of 
antiviral treatment on the outcome of postnatally ac-
quired CMV infection and no treatment recommenda-
tions exist so far. There are, however, encouraging data 
about ganciclovir treatment in congenital infections  [24] . 
Positive effects of treatment have also been described in 
anecdotal reports of postnatal infections  [25, 26] . Com-
monly reported side effects of ganciclovir therapy include 
neutropenia and technical problems with the venous ac-
cess. Not rarely, one of these problems is responsible for 
early interruption of the planned long-term treatment. 
Among the potential long-term side effects of this treat-
ment are the reduced male fertility observed in animal 
studies and neurological effects described in adult pa-
tients  [27] . Valganciclovir, the oral bioavailable prodrug 
of ganciclovir, and maribavir, a new oral anti-cytomega-
lovirus drug might be potential alternatives in the future 
 [28, 29] . Recent pharmacokinetic and clinical studies of 
valganciclovir in the neonatal population with congenital 
infection are quite promising  [30–32] . Specific immuno-
globulin preparations do not seem to be a valuable ap-
proach  [33] . As the clinical situation remained critical de-
spite intensive care and broad-spectrum antibiotic ther-
apy, in our patient we opted for starting intravenous 
ganciclovir-based antiviral therapy. Over the next days, 
we observed an impressive clinical improvement and a 
rapid disappearance of CMV DNA detectable by PCR in 
urine and tracheal aspirates.
 Outcome? 
 Although postnatally acquired CMV infection shows 
a spontaneous resolution in the vast majority of term in-
fants, mortality is estimated to be up to 10% in severely 
symptomatic preterm patients infected through transfu-
sion. Long-term effects of postnatally acquired CMV in-
fection in premature neonates are a matter of debate. 
Some data suggest an increased risk of bronchopulmo-
nary dysplasia, however, this is contradicted by others  [25, 
34, 35] . Neurological sequels that are frequently reported 
in congenitally infected patients (progressive chorioreti-
nitis, permanent neurosensorial hearing loss, seizures or 
developmental delay) have so far not been clearly demon-
strated in postnatally acquired infections  [36] . A case con-
trol study from the 1980s did not show an increase in the 
risk of moderate or major handicap in CMV-infected low 
birthweight patients. Nevertheless, the risk of severe 
handicap was greater in very preterm infants when CMV 
infection was acquired early (within the first 8 postnatal 
weeks)  [37] . In contrast, in a recent report comparing 22 
postnatally infected very preterm patients with 22 matched 
counterparts, no difference in the rate of sensorineural 
hearing loss, neurological anomalies or developmental 
delay was found at the age of 2.5–4 years  [38] . In this se-
ries, 3 of the 4 patients presenting with sepsis-like symp-
toms had some abnormalities on follow-up. However, all 
these patients, like the case reported here, were the most 
immature of the series, with a gestational age of  ! 25 
weeks. Our patient showed transient hypoacusis over the 
first few months which resolved at 1 year of corrected age, 
a finding which is not uncommon in the very premature 
population. A similar observation was reported recently 
by Takahashi et al.  [4] . Intracerebral calcifications were 
described in 2 preterm infants following postnatal infec-
tion  [39] . In our patient, repeated cerebral ultrasound ex-
aminations remained normal, but 2 cerebral MRIs showed 
moderate anomalies of the periventricular white matter 
and micro-hemorrhages in the posterior fossa. A causal 
relationship with the infection is uncertain as these find-
ings are unspecific and rather common in ELBW infants. 
However, so far there is no literature available on charac-
teristic cerebral MRI findings in postnatally acquired 
CMV infection. The neurodevelopmental course of the 
patient presented here is common to ELBW infants, with 
no clear developmental sequels of CMV infection so far. 
In the absence of conclusive literature as to the innocu-
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ousness of postnatal CMV infection in premature pa-
tients, careful and long-term neurodevelopmental follow-
up, with auditory monitoring, should be offered. Onset of 
late and progressive manifestations as described in con-
genital CMV disease should be considered.
 Prevention? 
 Freezing of breast milk can reduce the viral load but 
not prevent the risk of CMV infection  [2, 5, 40] . Standard 
pasteurization procedures (30 min at 62.5 ° C) are efficient 
to inactivate CMV but disturb important enzyme activity 
and reduce the nutritional and immunological quality of 
human milk  [17] . There is increasing evidence that short 
pasteurization procedures might be of similar efficiency 
to reduce CMV infectivity with the advantage of altering 
the immunological and nutritional components of the 
breast milk to a lesser degree  [41] . General precautions in 
blood transfusions and in hand hygiene of caregivers 
should be applied. Intensive research is ongoing regarding 
a CMV vaccine, but so far none is available  [42] .
 Conclusion 
 The report of this severe case of postnatally acquired 
CMV infection aims at raising the index of suspicion to-
wards its highly heterogeneous and unspecific clinical 
picture which can lead to under-, mis- or delayed diagno-
sis. We suggest that postnatal CMV infection should be 
considered in all breast milk-fed preterm infants of sero-
positive mothers presenting during the first 12 postnatal 
weeks with infectious symptoms and accompanying 
manifestations such as thrombocytopenia, hepatospleno-
megaly, cholestasis, pneumonitis, enterocolitis and/or 
sepsis-like signs. Diagnosis can be made by PCR detec-
tion of CMV DNA in urine, blood or tracheal aspirates. 
A PCR assay can also be retrospectively performed on an 
early sample of blood (e.g. on dried blood of metabolic 
screening cards) in an attempt to differentiate between 
prenatal and postnatal infection. Although the prognosis 
of postnatally acquired infection seems better than that 
of the congenital disease, treatment with intravenous 
ganciclovir may be considered in the very sick preterm 
infant. Additional data are needed to determine whether 
this treatment is of benefit for controlling the acute infec-
tion and also preventing long-term neurosensorial se-
quels.
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